No Prescription |
 |
 | ||
|
Valtan Diovan |
|
| ||
No Prescription » Prescription Drugs 16 » Valtan Diovan This drug is used to treat high blood pressure (hypertension) and heart failure. High blood pressure reduction helps prevent strokes heart attacks and kidney problems. This drug works by blocking the hormone angiotensin thereby relaxing blood vessels causing them to widen. Valsartan belongs to a class of drugs called angiotensin receptor blockers. Buy Valtan Diovan and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Valtan Diovan: Product Type: Prescription Drugs 16 Valtan ( Diovan Generic Valsartan ) Valtan (Diovan Generic Valsartan) Diovan Generic Valsartan 320mg Diovan Generic Valsartan Valtan
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
